AnaptysBio as a Pure Royalty Manager: Jemperli Dynamics and the Overlooked Imsidolimab Potential Justify $95 Price Target
Reading Time: 3 minutes
AnaptysBio (ANAB) underwent a massive structural transformation in spring 2026 and now offers investors an entirely new risk profile. With the successful spin-off of the capital-intensive in-house clinical research into the new company First Tracks Biotherapeutics in April 2026, the firm will operate as a pure royalty management company. From the management's perspective, this strategic move allows for a drastic reduction in operating costs while maximizing margins from existing drug partnerships. The appointment of a new Chief Financial Officer...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
